Bioxyne Limited · ASX:BXN
Bioxyne — Investor Presentation (April 2012)
29 slides from Bioxyne's investor presentation, Apr 26, 2012
Slide 1: David Radford CEO, April 2012
For personal use only David Radford CEO April 2012 26/04/12 1
Slide 2: Our mission
For personal use only Our mission is to identify and develop, a range of therapies based on technology utilising the application of mucosal immunology to treat common human diseases 26/04/12 2
Slide 3: Agenda
Agenda For personal use only • Who we are • Short-term focus – COPD therapy • Long-term opportunities • Forthcoming milestones • Summary • Appendices 26/04/12 3
Slide 4: Bioxyne – Who we are
For personal use only BIOXYNE – WHO WE ARE 26/04/12 4
Slide 5: Corporate overview
Corporate overview For personal use only • Created by merger of Hunter Immunology and Probiomics Limited in April 2012 • Listed on ASX (BXN), market cap AU$30m • Commercialising proprietary immunotherapy technology with multiple applications – Immediate focus on the commercialisation of therapeutic
Slide 6: Commercially-focused management and board
Commercially-focused management and board For personal use only Ian Mutton Chairman and Non-Executive Director David Radford CEO and Non-executive Director Former CEO of Nanosonics Doug Wilson Non-Executive Director Former Medical Director, Boehringer Ingelheim Jeremy Curnock Cook Non-Executive Dire
Slide 7: Financial and shareholder snapshot
Financial and shareholder snapshot For personal use only ASX code: BXN Major shareholders: Market cap: ~$30 million • Octa Phillip Asset Mgmt 21% Shares on issue: 149 million • Dr Philip Comans 9.6% Reported Cash: $2.49million • Mr Chris Cuffe 7.0% Top-20 holders: 66.2% • PT Soho Industri Pharma 6.5
Slide 8: A short-term opportunity: HI-164OV to treat COPD
For personal use only A SHORT-TERM OPPORTUNITY HI-164OV TO TREAT COPD 26/04/12 8
Slide 9: Novel treatment for COPD
Novel treatment for COPD For personal use only • Based on proprietary technology platform • Solid intellectual property estate • Lead asset is HI-1640V, a novel therapy to mitigate the symptoms of ‘exacerbations’ caused by respiratory infections in patients with COPD – Phase IIb human clinical trial
Slide 10: COPD – urgent need for improved therapy
COPD – urgent need for improved therapy For personal use only • COPD is characterised by: – Emphysema and chronic bronchitis – Reduced airways capacity – Exacerbations - sudden worsening of symptoms • Traditionally associated with smokers but today ~20% of newly diagnosed patients have never smoked
Slide 11: What is HI-1640V
What is HI-1640V For personal use only • HI-164OV is a novel immunotherapy designed to improve outcomes when used in combination with current standard of care – Does not seek to change medical practice. Complimentary to existing therapies • It is an‘enteric-coated tablet’ containing killed H.influen
Slide 12: COPD – market is significant
COPD – market is significant For personal use only • COPD is a major target of global pharmaceutical research • Global incidence growing rapidly in direct proportion to smoking and pollution in the developing world (BRIC - Brazil, Russia, India, Indonesia, China ) • COPD is a major cause of morbidit
Slide 13: HI-1640V – achievements to date
HI-1640V – achievements to date For personal use only • Positive Phase IIa human clinical trial results • Primary end points: Number of episodes of acute bronchitis; duration of bronchitis and number of courses of antibiotics – 38 patient trial for moderate to severe COPD showed HI-1640V reduced hos
Slide 14: Phase IIb study nearing completion
Phase IIb study nearing completion For personal use only • Phase IIb 320 patients multi-centre trial – 292 Patients have completed the study (March 2012) – 21 hospitals around Australia – Stringent Double Blinded Protocol • No signal of safety issues from first 100 patients • >180 Adverse Events to
Slide 15: HI-1640V – the measure of success
HI-1640V – the measure of success For personal use only • It is anticipated that a reduction in hospitalisation could deliver significant economic benefits • Subject to results of Phase IIb trial in June, strategy to explore opportunities to licence, partner or sell – Early discussions with potentia
Slide 16: Long-term opportunities: therapeutics and probiotics
For personal use only LONG-TERM OPPORTUNITIES THERAPEUTICS AND PROBIOTICS 26/04/12 16
Slide 17: A business with multiple opportunities
A business with multiple opportunities For personal use only HI164-OV Therapeutic Therapeutics Probiotics COPD Phase IIb Asthma Lactobacillus pre-clinical fermentum VRI003 evaluations Marketed Otitis media patent lodged. Under evaluation 17
Slide 18: Risk-balanced strategic options
Risk-balanced strategic options For personal use only Human therapeutics Therapeutic probiotics HI-164OV Positive data from Phase IIb COPD trial Sale of IP - Co-development/ Exploit mucosal Immediate opportunities commercialisation deal commercialisation deal immunology platform to leverage potentia
Slide 19: Forthcoming milestones
For personal use only FORTHCOMING MILESTONES 26/04/12 19
Slide 20: Results focused commercialisation strategy
Results focused commercialisation strategy For personal use only Milestone-driven and outcomes focused 2013 Q2-‐2013 Further development License/JV/ of Sale of therapeu-c Q2-‐2012 HI-‐164OV applica-ons Phase IIb trial results HI-‐164OV Q1-‐2012 ASX lis-ng-‐ Bioxyne 26/04/12 20
Slide 21: Summary
For personal use only 26/04/12 SUMMARY 21
Slide 22: Summary
Summary For personal use only • Commercially-focused Sydney-based ASX-listed immunotherapeutics company • Potential to create world-class business based on mucoscal immunology platform • Short term opportunity for value creation from lead therapy HI-164OV, being developed to address major unmet clin
Slide 23: Appendices
For personal use only 26/04/12 APPENDICES 23
Slide 24: Solid intellectual property estate
Solid intellectual property estate For personal use only Patent Descrip-on Filing Date Jurisdic-on PT004 Asthma Treatment March 2008 Major Interna-onal countries PT006 ETxB Carrier Protein June 2002 USA/WIPO PT011 HI-‐164 Isolate Sept 2009 Major Interna-onal countries PT001 Isolate Selec-on August
Slide 25: COPD market in AU, UK and US
COPD market in AU, UK and US For personal use only COPD Hospitalisation Average Days of Country Events/Annum Hospitalisation Reference Australia >54,000 7.5 www.cancerwa.asn.au/ resources/2009-12-22- facts- on copd& smoking United Kingdom >109,000 10 Halpin & Miravitlles-COPD The Disease and its bur
Slide 26: Market Sizing – COPD
Market Sizing – COPD For personal use only • An average of >10% of the population >40 has some form of COPD 26/04/12 26
Slide 27: Recent respiratory transactions
Recent respiratory transactions For personal use only Company Partner Value Roche (2010) Galapagos >USD580m Forest (2009) Nycomed USD100m (US rights only) J&J 2 respiratory deals e.g Not public Acquisition of Respivert Boehringer Ingelheim Milestone driven Not public (2008) deals. Partner not disclo
Slide 28: Clinical Publications – HI-164OV
Clinical Publications – HI-164OV For personal use only "... moderate-to-severe exacerbations were reduced by 63%. The proportion with any acute exacerbation was little changed with treatment, but the proportion with episodes requiring corticosteroid therapy was reduced by 56%. The mean duration of e
Slide 29: For personal use only
For personal use only 26/04/12 29